{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:28:04Z","timestamp":1786969684134,"version":"build-2736575974"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T00:00:00Z","timestamp":1781049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"DOI":"10.1186\/s13287-026-05088-0","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T01:35:59Z","timestamp":1781055359000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Temporal dynamics of substance P and its association with cytokine release syndrome after CD19 CAR-T therapy in pediatric B-ALL"],"prefix":"10.1186","volume":"17","author":[{"given":"\u00c1gueda","family":"Molinos-Quintana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Rodr\u00edguez-Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Caballero-Vel\u00e1zquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Estefan\u00eda","family":"Garc\u00eda-Guerrero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Alcalde-Mellado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Hern\u00e1ndez-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Delgado-Serrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Ruiz-Maldonado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Mu\u00f1oz-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Luis","family":"Reguera-Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elia","family":"S\u00e1nchez-Valderr\u00e1banos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Antonio","family":"P\u00e9rez-Sim\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,10]]},"reference":[{"key":"5088_CR1","first-page":"51","volume":"3","author":"TE Klassert","year":"2010","unstructured":"Klassert TE, Patel SA, Rameshwar P. Tachykinins and neurokinin receptors in bone marrow functions: neural-hematopoietic link. J Receptor Ligand Channel Res. 2010;3:51\u201361.","journal-title":"J Receptor Ligand Channel Res"},{"key":"5088_CR2","first-page":"22","volume":"294","author":"JP Aversa","year":"2016","unstructured":"Aversa JP, Dente F. The role of substance P in the neuroimmune modulation of hematopoiesis. J Neuroimmunol. 2016;294:22\u20139.","journal-title":"J Neuroimmunol"},{"key":"5088_CR3","first-page":"54","volume":"13","author":"C G\u00e9rard","year":"2019","unstructured":"G\u00e9rard C, M\u00f6ller T. Substance P and neuroimmune interactions in the bone marrow. Front Neurosci. 2019;13:54.","journal-title":"Front Neurosci"},{"key":"5088_CR4","doi-asserted-by":"publisher","first-page":"4249","DOI":"10.1007\/s00018-016-2293-z","volume":"73","author":"A Mashaghi","year":"2016","unstructured":"Mashaghi A, Marmalidou A, Tehrani M, Grace PM, Pothoulakis C, Dana R. Neuropeptide substance P and the immune response. Cell Mol Life Sci. 2016;73:4249\u201364.","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"5088_CR5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1189\/jlb.0610381","volume":"89","author":"SD Douglas","year":"2010","unstructured":"Douglas SD, Leeman SE. Neurokinin-1 receptor: functional significance in the immune system. J Leukoc Biol. 2010;89(1):57\u201366.","journal-title":"J Leukoc Biol"},{"key":"5088_CR6","first-page":"116","volume":"14","author":"J Mei","year":"2020","unstructured":"Mei J, Xie J. Substance P and its role in pain and inflammation: An updated review. Front Neurosci. 2020;14:116.","journal-title":"Front Neurosci"},{"issue":"1","key":"5088_CR7","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1189\/jlb.0408260","volume":"85","author":"I Chernova","year":"2009","unstructured":"Chernova I, Lai JP, Li H, Schwartz L, et al. Substance P enhances CCL5-induced chemotaxis and intracellular signaling in human monocytes, which express the truncated neurokinin-1 receptor. J Leukoc Biol. 2009;85(1):154\u201364.","journal-title":"J Leukoc Biol"},{"key":"5088_CR8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jneuroim.2006.07.010","volume":"180","author":"EK Reinke","year":"2006","unstructured":"Reinke EK, Johnson MJ, et al. Substance P receptor mediated maintenance of chronic inflammation in EAE. J Neuroimmunol. 2006;180:117\u201325.","journal-title":"J Neuroimmunol"},{"key":"5088_CR9","first-page":"91","volume":"25","author":"X Huang","year":"2024","unstructured":"Huang X, et al. Advances in the research and application of neurokinin-1 receptor antagonists. Front Pharmacol. 2024;25:91\u2013105.","journal-title":"Front Pharmacol"},{"key":"5088_CR10","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378:439\u201348.","journal-title":"N Engl J Med"},{"key":"5088_CR11","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1200\/JCO.22.00642","volume":"41","author":"TW Laetsch","year":"2023","unstructured":"Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, et al. Three-year update of tisagenlecleucel in pediatric and young adult patients with relapsed or refractory acute lymphoblastic leukemia in the ELIANA trial. J Clin Oncol. 2023;41:1664\u201375.","journal-title":"J Clin Oncol"},{"key":"5088_CR12","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transpl. 2019;25:625\u201338.","journal-title":"Biol Blood Marrow Transpl"},{"key":"5088_CR13","doi-asserted-by":"publisher","first-page":"3978","DOI":"10.1200\/JCO.21.01992","volume":"39","author":"BD Santomasso","year":"2021","unstructured":"Santomasso BD, Nastoupil LJ, Adkins S, Lacchetti C, Schneider BJ, Anadkat M, et al. Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline. J Clin Oncol. 2021;39:3978\u201392.","journal-title":"J Clin Oncol"},{"key":"5088_CR14","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","volume":"24","author":"T Giavridis","year":"2018","unstructured":"Giavridis T, van der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain M. CAR T cell\u2013induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018;24:731\u20138.","journal-title":"Nat Med"},{"key":"5088_CR15","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24:739\u201348.","journal-title":"Nat Med"},{"key":"5088_CR16","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","volume":"7","author":"J Gust","year":"2017","unstructured":"Gust J, Hay KA, Hanafi LA, Li D, Myerson D, Gonzalez-Cuyar LF, et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 2017;7:1404\u201319.","journal-title":"Cancer Discov"},{"issue":"4","key":"5088_CR17","first-page":"364","volume":"2","author":"RJ Turner","year":"2023","unstructured":"Turner RJ, Nimmo AJ. Evidence for the involvement of the tachykinin NK1 receptor in acute inflammation of the central nervous system. NeuroSci. 2023;2(4):364\u201377.","journal-title":"NeuroSci"},{"key":"5088_CR18","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3389\/fimmu.2019.00036","volume":"10","author":"L M\u00e1rquez","year":"2019","unstructured":"M\u00e1rquez L, Saggini A. Neuroimmune interactions: The role of substance P in inflammation. Front Immunol. 2019;10:36.","journal-title":"Front Immunol"},{"issue":"3","key":"5088_CR19","first-page":"315","volume":"51","author":"D Levy","year":"2006","unstructured":"Levy D, Hirth D. Substance P and inflammation: Implications for treatment of inflammatory diseases. Neuropharmacology. 2006;51(3):315\u201320.","journal-title":"Neuropharmacology"},{"key":"5088_CR20","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1128\/IAI.00358-08","volume":"76","author":"AM Blum","year":"2008","unstructured":"Blum AM, Setiawan T, et al. Interleukin-12 and IL-23 induction of substance P synthesis in murine T cells and macrophages is subject to IL-10 and transforming growth factor-\u03b2 regulation. Infect Immun. 2008;76:3651\u20136.","journal-title":"Infect Immun"},{"key":"5088_CR21","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","volume":"130","author":"KA Hay","year":"2017","unstructured":"Hay KA, Hanafi LA, Li D, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor modified T-cell therapy. Blood. 2017;130:2295\u2013306.","journal-title":"Blood"},{"issue":"5","key":"5088_CR22","first-page":"1255","volume":"101","author":"M Steinhoff","year":"2017","unstructured":"Steinhoff M, von Mentzer B. Substance P and neurokinin receptors in inflammation and immunity. J Leukoc Biol. 2017;101(5):1255\u201369.","journal-title":"J Leukoc Biol"},{"key":"5088_CR23","unstructured":"U.S. Food and Drug Administration. EMEND\u00ae (fosaprepitant dimeglumine) for Injection: Prescribing Information. Silver Spring, MD: FDA; 2008. Disponible en: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/022023lbl.pdf"},{"key":"5088_CR24","doi-asserted-by":"publisher","first-page":"495704","DOI":"10.1155\/2015\/495704","volume":"2015","author":"S Garcia-Recio","year":"2015","unstructured":"Garcia-Recio S, Gasc\u00f3n P. Biological and pharmacological aspects of the NK1-receptor. Biomed Res Int. 2015;2015:495704. https:\/\/doi.org\/10.1155\/2015\/495704.","journal-title":"Biomed Res Int"},{"issue":"2","key":"5088_CR25","first-page":"284","volume":"41","author":"X Liu","year":"2019","unstructured":"Liu X, Zhang Y, Lu W, Li L, Xu H, Jin X, et al. Antagonism of NK-1R using aprepitant suppresses TNF-\u03b1-induced expression of IL-1\u03b2, IL-6, and IL-8 in fibroblast-like synoviocytes. Immunopharmacol Immunotoxicol. 2019;41(2):284\u201390.","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"5088_CR26","doi-asserted-by":"crossref","first-page":"115152","DOI":"10.1016\/j.biopha.2023.115152","volume":"165","author":"P Jin","year":"2023","unstructured":"Jin P, et al. Neurokinin receptor 1 antagonist aprepitant alleviates lipopolysaccharide-induced inflammation by inhibiting NF-\u03baB pathway activation. Biomed Pharmacother. 2023;165:115152.","journal-title":"Biomed Pharmacother"},{"key":"5088_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.112159","volume":"143","author":"R Mehboob","year":"2021","unstructured":"Mehboob R. Neurokinin-1 receptor as a potential drug target for COVID-19 treatment. Biomed Pharmacother. 2021;143:112159. https:\/\/doi.org\/10.1016\/j.biopha.2021.112159.","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"5088_CR28","first-page":"371","volume":"36","author":"MC Cuesta","year":"2002","unstructured":"Cuesta MC, Quintero L, Pons H, Su\u00e1rez-Roca H. Substance P and calcitonin gene-related peptide increase IL-1\u03b2, IL-6 and TNF-\u03b1 production in human peripheral blood mononuclear cells. Neuropeptides. 2002;36(6):371\u20138.","journal-title":"Neuropeptides"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-026-05088-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-026-05088-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-026-05088-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T12:03:28Z","timestamp":1786968208000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13287-026-05088-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,10]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5088"],"URL":"https:\/\/doi.org\/10.1186\/s13287-026-05088-0","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,10]]},"assertion":[{"value":"14 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Ethics Committee of the Hospitales Universitarios Virgen Macarena y Virgen del Roc\u00edo (Seville, Spain) under the project entitled \u201cPrediction of response to CAR-T cell therapy: biomarker discovery and metabolic activity assessment through immune monitoring\u201d (original title in Spanish: \u201cPredicci\u00f3n de la respuesta del tratamiento con c\u00e9lulas CAR-T: b\u00fasqueda de biomarcadores y medici\u00f3n de la actividad metab\u00f3lica mediante monitorizaci\u00f3n inmune\u201d) (approval number: 1458-N-21; protocol code: S2100234; date of approval: 20 July 2021). Written informed consent for participation in the study and for the use of biological samples was obtained from all patients\u2019 legal guardians in accordance with institutional guidelines and the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"An AI-based image generation tool was employed exclusively to create a schematic representation of the proposed hypothesis for illustrative purposes (fig.\n                      \n                      ).","order":3,"name":"Ethics","label":"Use of AI tools","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"280"}}